AA-METOPROLOL SR TABLET (EXTENDED-RELEASE)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
12-10-2022
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
METOPROLOL TARTRATE
Inapatikana kutoka:
AA PHARMA INC
ATC kanuni:
C07AB02
INN (Jina la Kimataifa):
METOPROLOL
Kipimo:
200MG
Dawa fomu:
TABLET (EXTENDED-RELEASE)
Tungo:
METOPROLOL TARTRATE 200MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100
Dawa ya aina:
Prescription
Eneo la matibabu:
BETA-ADRENERGIC BLOCKING AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0111923001; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2022-10-13
Tabia za bidhaa
_AA-METOPROLOL SR (Metoprolol Tartrate Tablets) _
_ _
_Page 1 of 42 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
AA-METOPROLOL SR
Metoprolol Tartrate Prolonged-release Tablets
Prolonged-release tablets, 100 mg and 200 mg, oral
House Standard
Beta-Adrenergic Receptor Blocking Agent
AA Pharma Inc.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Date of Revision:
October 12, 2022
Submission Control Number: 262717
_AA-METOPROLOL SR (Metoprolol Tartrate Tablets) _
_ _
_Page 2 of 42 _
RECENT MAJOR LABEL CHANGES
Not applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
....................................................................................................................4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS.......................................................................................................5
4
DOSAGE AND ADMINISTRATION
.......................................................................................5
4.1
Dosing Considerations
................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
............................................................. 6
4.4
Administration............................................................................................................
8
4.5
Missed Dose
.
Soma hati kamili
